about
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degenerationComplement inhibitors for age-related macular degenerationInterventions for neovascular age-related macular degenerationTrends in provision of photodynamic therapy and clinician attitudes: a tracker survey of a new health technologyDefining response to anti-VEGF therapies in neovascular AMDThe design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease.A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degenerationAlternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialRelation between macular morphology and visual function in patients with choroidal neovascularisation of age related macular degenerationHeritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypesCLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.External beam radiotherapy in exudative age-related macular degeneration: a pooled analysis of phase I data.Retinal pigment epithelial cell DNA is damaged by exposure to benzo[a]pyrene, a constituent of cigarette smoke.Macular pigment and age-related macular degeneration: longitudinal data and better techniques of measurement are needed.Evolving European guidance on the medical management of neovascular age related macular degeneration.Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking.FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.Prevalence of early and late age-related macular degeneration in India: the INDEYE study.An ecological correlation study of late age-related macular degeneration and the complement factor H Y402H polymorphism.Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.DNA-based eye colour prediction across Europe with the IrisPlex system.Associations between aspirin use and aging macula disorder: the European Eye Study.VEGF-targeted therapy and beyond: pharmacotherapy and emerging treatments in agerelated macular degeneration.Prevalence and risk factors for vitamin C deficiency in north and south India: a two centre population based study in people aged 60 years and over.Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.EPHA2 polymorphisms and age-related cataract in India.Systemic safety of anti-VEGF drugs: a commentary.Small RNAs from plants, bacteria and fungi within the order Hypocreales are ubiquitous in human plasma.Blood levels of vitamin C, carotenoids and retinol are inversely associated with cataract in a North Indian population.The effect of lutein- and zeaxanthin-rich foods v. supplements on macular pigment level and serological markers of endothelial activation, inflammation and oxidation: pilot studies in healthy volunteers.The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degenerationEvidence underlying the clinical management of diabetic macular oedema.Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older peoplePrevalence of cataract in an older population in India: the India study of age-related eye diseaseCommon variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration.Inverse association of vitamin C with cataract in older people in IndiaA vision specific functional index for use in patients with age related macular degeneration.Macular degeneration: do conventional measurements of impaired visual function equate with visual disability?Amblyopia: is visual loss permanent?Health professionals' and service users' perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trial.
P50
Q24193614-9627E082-ED95-4F3B-8E8C-3D8FD16E7776Q24201117-9E46976F-2201-4C50-9EA5-8DB98D8AE30BQ24240728-9B33020A-44D0-4FFF-AB7C-7AA3FA5E8B0FQ24810252-4C5678D1-B961-4F31-A90D-96E7F03A06C4Q26996510-4740CFA5-844A-455D-B225-4A3E66F6969CQ27324293-ED8BFE63-EEB4-4905-B3AB-1D0580D89535Q28265296-8E1EF175-7BCE-496E-8581-AC4FD5E59D57Q28294837-7599B77C-DB54-4B32-90C6-E900FA3B5B47Q28346336-768354D0-C9C1-4D7B-8035-6BAD2D24E86AQ28943546-3E66A84E-A8C2-4DA6-B101-8CB3E3820037Q30491050-9BB3AD3E-1FFB-436B-9988-B923B850ABD4Q30596443-E94DC974-7A12-4350-A312-D55D34E73EACQ31083440-3A62071F-BCDB-4D2E-B981-267CA86E5B6CQ31149023-DEF6DD5B-92DD-4740-B945-948B0DDC58B1Q33255038-2C76EEED-8A2D-4862-9FC1-234F75E4DF3BQ33312508-BAD3FC44-AF45-455D-9607-94B40894DBA4Q33816926-BD4CB83F-2DFF-4599-A025-54B01D4315ECQ33845354-AFE2D218-0EEF-4A9E-BA6C-A9FA2CA7D2EAQ33845500-9B4DEAA9-4D2E-4C41-A5E1-E78CB76AF1F4Q33995880-A320B551-8B90-4AF0-A51B-5B6F8EA8C284Q34027976-5E3D2D01-D92E-4BB4-B74B-945FFE2E37ACQ34028568-1D15D33B-E147-4595-85AD-6ECDA56ACA6FQ34081923-49331392-6D25-4E9E-AC16-D1CAFA4297CCQ34097930-19B7F55C-B245-40AD-8658-97770F5BA65CQ34164115-422E5D75-F153-412C-ADA1-A0DD03396898Q34193609-D624B07C-A96B-4C1C-A751-651F4C3BDC35Q34452811-91F1A117-E0F6-4E73-BFA6-9F8896912CFCQ34505062-48FAA456-83C8-49D4-8B71-56D34A5B94E2Q34590742-F64899CA-2CF4-4594-86CB-BF3CE2E45302Q34635706-AB9E5DF7-749F-449E-862C-83A9A5CFC3F0Q34674568-BE682B8A-5E27-482B-A393-018ED35E23FAQ34889065-FC3A65C6-9B87-43A0-A60F-6270B3A54113Q35133129-60478F36-A977-489D-B4D0-B068CB0B146EQ35136887-743F309D-8895-4978-B28E-6917EB74D5A9Q35175046-423FEBC0-7699-4572-8B53-61D0DA87BE82Q35256873-79D42CE3-A97A-46AC-8315-172684F7DB90Q35307622-A8E35B54-6B44-4933-9C93-D93F59453540Q35313669-737CE877-984C-4733-A6F8-1D16C550BD68Q35316568-9072D904-8996-462E-9970-2EA45ECFE18AQ35539416-DCE27CF1-D88B-433E-8663-7BA2B0D90515
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Usha Chakravarthy
@ast
Usha Chakravarthy
@en
Usha Chakravarthy
@es
Usha Chakravarthy
@nl
Usha Chakravarthy
@sl
type
label
Usha Chakravarthy
@ast
Usha Chakravarthy
@en
Usha Chakravarthy
@es
Usha Chakravarthy
@nl
Usha Chakravarthy
@sl
prefLabel
Usha Chakravarthy
@ast
Usha Chakravarthy
@en
Usha Chakravarthy
@es
Usha Chakravarthy
@nl
Usha Chakravarthy
@sl
P244
P106
P1153
35482816500
P214
8150170482300012098
P244
nb2017015290
P31
P496
0000-0002-2606-3734
P734
P7859
lccn-nb2017015290